The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has seen substantial growth in recent years. It is expected to expand from $6.11 billion in 2025 to $6.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. This historical growth can be attributed to an increase in the prevalence of chronic pancreatitis, greater awareness of digestive disorders, limited access to specialized diagnostics, the uptake of nutritional supplements, and the expansion of home healthcare services.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is anticipated to show robust expansion in the coming years. It is projected to achieve a size of $8.97 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.2%. This expansion during the forecast period is attributable to advancements in personalized enzyme therapies, the integration of AI in diagnostics, a rising demand for non-invasive imaging, the broadening of telehealth services, and an increasing emphasis on patient-centric nutritional management. Key trends for the forecast period include advanced pancreatic enzyme replacement therapies, point-of-care diagnostic solutions, personalized nutritional management programs, non-invasive imaging techniques for epi, and the incorporation of telehealth into epi management.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What Key Drivers Are Influencing The Growth Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The rising prevalence of diabetes is anticipated to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market moving forward. Diabetes is defined as a chronic metabolic ailment marked by consistently elevated blood sugar levels (hyperglycemia) over an extended period, resulting from the body’s insufficient insulin production or its ineffective utilization. EPI treatment, primarily pancreatic enzyme replacement therapy (PERT), aids in enhancing nutrient absorption and can also assist in better glycemic control for individuals with diabetes and EPI. For instance, data from June 2024, provided by The National Health Service (NHS England), a UK-based publicly funded healthcare system, indicated that the count of individuals identified by the NHS in England with pre-diabetes reached 3,615,330 in 2023, representing an 18% increase from 3,065,825 in 2022. Furthermore, among those aged under 40, cases saw a surge of nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing number of people affected by diabetes is a key driver for the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
What Major Segment Divisions Exist Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
How Are Trends Shaping The Direction Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Leading businesses in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are utilizing a strategic partnership method to improve technology integration and expand their market reach. A strategic partnership usually indicates a cooperative relationship between two or more organizations where they merge their assets, knowledge, and efforts to achieve mutual goals or objectives. As an illustration, in February 2023, Codexis, Inc., a protein engineering company based in the US, and Nestlé Health Science, a nutrition science firm from Switzerland, disclosed interim outcomes from their Phase 1 clinical trial of CDX-7108, an experimental treatment intended for exocrine pancreatic insufficiency (EPI). The findings from this Phase 1 trial prepare the ground for future investigations that have the potential to considerably enhance therapeutic choices for EPI patients.
Which Companies Are Leading Innovation In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd
Read the full exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report here:
Which Region Is Expected To Register The Fastest Growth In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company
Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026
Exocrine Pancreatic Insufficiency Market Report 2026
Acute Pancreatitis Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model